Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.

Key facts

Study ID

NCT00231569

Run by

Kastle Therapeutics, LLC

People needed

74

Starts

2005-09-01

Expected to finish

2007-12-01

Last updated by the study team

2016-08-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• On a stable dose of >/= 40 mg Simvastatin or atorvastatin daily for >/= 3 months prior to baseline and expected to remain on this dose for the remainder of the study
• LDL-cholesterol between 2.60 and 5.70 mmol/L (100 and 220 mg/dL), inclusive at screening
• Females not of childbearing potential.

You may not qualify if…

• History of CHD or CHD-equivalent (such as diabetes mellitus, or another clinical form of atherosclerotic disease, e.g., peripheral arterial disease, abdominal aortic aneurysm, or symptomatic carotid artery disease)
• Fasting triglyceride >2.26 mmol/L (200 mg/dL) at screening
• Any uncontrolled medical/surgical/psychiatric condition, including conditions that may predispose to secondary hypercholesterolemia
• Current diagnosis or known history of complement deficiency or abnormality
• A positive hepatitis B surface antigen or hepatitis C antibody, or a known positive HIV status
• Current diagnosis or known history of liver disease, or has an ALT >ULN at screening
• Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained muscle pain, or has a CPK >ULN at screening
• Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been adequately treated
• The advisability of a subject taking any prescription medication (apart from simvastatin or atorvastatin) within 6 weeks prior to screening should be discussed with the Isis Medical Monitor
• Subject unwilling to discontinue taking alternative/herbal medication for the duration of the study
• History of drug abuse within 2 years of screening
• Subject unwilling to limit alcohol consumption for the duration of the study: male subjects to a maximum of 3 drinks (30 g) per day, and <12 drinks (120 g) per week; female subjects to a maximum of 2 drinks (20 g) per day, and <8 drinks (80 g) per week
• Known allergy or hypersensitivity to simvastatin
• Undergoing or has undergone treatment with another investigational drug, biologic agent, or device within 3 months, or 3 half lives, prior to screening, whichever is longer

Where it is running

• Study site — Auburn, Maine, United States
• Study site — Amsterdam, Netherlands
• Study site — Leiden, Netherlands
• Study site — Rotterdam, Netherlands
• Study site — Utrecht, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.